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Abstract: Stroke is one of the most devastating complications of bone fracture, occurring in up to
4% of patients after surgical repair for hip fracture. Bone fracture and ischemic stroke have many
common risk factors. The impact of bone fracture on stroke recovery has not drawn much attention in
the research field. Bone fracture could occur in stroke patients at different times during the recovery
phase, which steepens the trajectory of cognitive decline, greatly affects the quality of life, and causes
a heavy burden on healthcare resources. In this paper, we reviewed the growing information on the
pathophysiological mechanisms by which bone fracture may affect ischemic stroke recovery process.
Keywords: bone fracture; stroke; cognitive decline; inflammation
1. Introduction
Up to 5% of stroke victims sustain a bone fracture [1–6]. The risk of stroke doubles after hip
fracture [7,8], and remains high 10 years after hip fracture [9]. Clinical scenarios of this combination
include stroke victims with bone-demineralization falling due to limb weakness resulting in bone
fracture; alternatively, an initial bone fracture causes hemorrhagic shock and systemic inflammation
that can precipitate an ischemic stroke. As advanced age is a risk factor for both stroke and fracture,
it is imperative to understand the neurobiologic underpinnings for the association of these two
conditions on the trajectory of aged-related cognitive decline. Stroke doubles the risk of developing
dementia [10] and cognitive impairment occurs in nearly half of hip fracture patients [11]. The aging
demographic change in the US will increase the burden of these diseases at both the individual and
societal levels.
Bone fracture and stroke can occur in different sequences. Patients with both injuries will have
less optimal outcomes than patients that have single injury. Although stroke and bone fracture have
many common risk factors [5,12,13], strategies for preventing [14,15] or treating stroke may adversely
influence bone healing [4].
Currently, there is no optimal strategy for prevention or treatment of post-stroke bone fracture
or post-bone fracture stroke. Intravenous thrombolysis is widely accepted, and tissue plasminogen
activator (tPA) is still the only drug approved by the U.S. Food and Drug Administration (FDA)
for the management of acute ischemic stroke [16,17]. However, the therapeutic time window for tPA
(<4.5 h post stroke) is quite narrow. Application of tPA beyond the therapeutic time window may
produce hemorrhagic transformation (HT), which increases morbidity and mortality in stroke patients.
Drugs that preserve the integrity of the blood-brain barrier (BBB) or enhance vascularization have been
tested to reduce tPA-induced HT [18]. It has been shown that the basement membrane disintegrated
and detached from the astrocyte endfeet in tPA-treated hypertensive rat model of middle cerebral
artery occlusion (MCAO). Edaravone, approved by the FDA recently to treat patients with amyotrophic
Int. J. Mol. Sci. 2018, 19, 1533; doi:10.3390/ijms19051533 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 1533 2 of 12
lateral sclerosis, prevented the dissociation of the neurovascular unit, dramatically decreased the HT,
and improved the neurologic score and survival rate of the tPA-treated rats [19]. G-CSF can also
attenuate delayed tPA-induced HT [20]. With the improvement of the technologies, the therapeutic
window for ischemic stroke is extending. For example, the window for thrombectomy has been
extended from 6 h to 24 h lately [21]. Other therapeutic strategies, such as stem cell therapy, can extend
the stroke therapy window further [22].
For most individuals who have not received thrombolysis, antiplatelet or anticoagulation,
therapy is recommended to decrease the incidence of recurrent stroke [16,23]. However, thrombolysis
or anticoagulation therapies can increase the incidence of bone fracture hemorrhage, and there are no
guidelines currently on the use of antithrombotic drugs for bone fracture patients [24].
Stroke and bone fracture share some common risk factors, such as hypertension and
diabetes mellitus [5,12]. Management of these risk factors to prevent stroke or bone fracture is
complicated. For example, using pioglitazone (a drug in the thiazolidinedione class of peroxisome
proliferator-activated receptor γ [PPAR-γ]—one of the most potent insulin-sensitizing drugs) to treat
insulin-resistant non-diabetes patients who have a history of stroke reduced the risk of stroke,
but increased the risk of bone fracture [14,15].
Despite the growing number of patients with both injuries, few studies have been designed
to address the impact of bone fracture/surgery on stroke recovery, which, if unabated, will lead to
an increased burden of these illnesses on individual suffering and healthcare resources. Due to the lack
of biological understanding of the interaction of these two conditions, there are no specific interventions
to prevent post-bone fracture/surgery stroke, nor post-stroke bone fracture. Understanding the
underlying mechanism could lead to the discovery of new targets for the development of innovative
therapies to improve the recovery of patients with stroke and bone fracture and reduce the health
care costs.
2. Bone Fracture Causes Hippocampal Inflammation and Cognitive Dysfunction
Peripheral trauma strike and surgery commonly cause mild transient cognitive impairment
among young and otherwise healthy patients [25,26]. However, long-term cognitive decline can
occur in patients with some risk factors, such as advanced age [27,28]. Advance age is the major
risk factor for the development of cognitive impairment and dementia [26,29,30]. Compared to
other hospitalized groups, cognitive dysfunction is present more often in orthopedic patients [31,32].
The elderly are prime candidates for hip- and/or knee-replacement surgeries, partly due to increased
rates of age-related bone fragility [33]. It has been estimated that 25–40% of the patients undergoing
non-cardiac surgery develop cognitive decline by the time of hospital discharge. The risk of dementia
remains significantly higher (>10%) among patients over 60 years old at 3 months after surgery [34,35].
Patients with Metabolic Syndrome appeared to have a greater likelihood of having impaired
cognitive function after either cardiac or non-cardiac surgery [36]. For patients with preexisting
cognitive decline—such as Alzheimer’s disease, or who are at risk for developing it—peripheral
trauma and surgery can deteriorate cognitive function and exacerbate neurodegeneration [37–39].
Gender factors also predispose to this post-trauma cognitive decline [40]. One longitudinal
cohort study on hip fracture patients found that poor functional outcomes were related to the baseline
pre-fracture dementia and cognitive impairment during hospitalization, which was more like to occur
in aged males [41].
Animal studies show that aseptic long bone fracture can cause neuroinflammation and cognitive
decline. In healthy, young animals, inflammatory cytokines, such as tumor necrosis factor-alpha
(TNFα), interleukin-1β (IL-1β) and Interleukin-6 (IL-6), are increased in peripheral blood and
hippocampus after aseptic tibia fracture, which is associated with short-term memory dysfunction [42].
Peripheral blockade of TNFα with antibody attenuated the increase of hippocampal IL-1β
after tibia fracture, suggesting that it is an upstream mediator [42]. Furthermore, the activation
of TNFα/nuclear factor (NF)-κB signaling pathway impairs the integrity of BBB, which increases
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peripheral macrophage infiltration into the hippocampus. All of these interfere with the processes
required for memory and learning [43,44].
Animals with risk factors suffer a longer period of cognitive dysfunction after peripheral
surgery [45]. The memory deficit in rats that were selectively bred for low exercise endurance to
mimic metabolic syndrome lasted more than 5 months post-operatively [38]. Our recent study found
that the spatial memory dysfunction in adult mice subjected to tibia fracture shortly before stroke
lasted beyond 8 weeks.
3. Bone Fracture Exacerbates Ischemic Stroke Injury
Animal studies have shown that bone fracture shortly before or after ischemic stroke exacerbates
stroke injuries. Mice that had tibia fracture 6 h before, one day before, or one day after the permanent
occlusion of distal middle cerebral artery (pMCAO) had more severe behavior deficits than mice
subjected to pMCAO alone. They took a longer time to remove the adhesive on the fore paw opposite
to the stroke side in the adhesive removal test, and made more turns to the stroke side during the
corner test [46–48]. The mice with bone fracture and pMCAO have larger infarct volumes and more
apoptotic neurons in the peri-infarct region than mice with stroke alone [46–48].
Tibia fracture occurring shortly before or after ischemic stroke enhanced inflammation in
the peri-infarct areas [46–48]. Mice with both injuries had higher levels of IL-6 in the ipsilateral
hemisphere [46,48], and more CD68+ cells in the peri-infarct regions compared to mice with pMCAO
only [46,48]. Both bone marrow-derived macrophages and active microglia are increased in mice
subjected to both injuries [46,48]. Intraperitoneal administration of a high-mobility group box 1 protein
(HMGB1)-neutralizing antibody attenuated fracture-enhanced infarct volume, apoptotic neurons in
the infarct area, the number of CD68+ cells in the peri-infarct region and behavioral dysfunction [46].
Using clodrolip to selectively deplete macrophages significantly reduced the number of CD68+ cells
in the peri-infarct region, the infarct volume and neurobehavioral dysfunction [46]. Microglia and
macrophages can polarize into type I (pro-inflammation, M1) and type II (anti-inflammation, M2)
phenotypes [49–51]. Tibia fracture increased the number of macrophages/microglia expressing
M1 markers (iNOS and CD11b) and reduced the number of macrophages/microglia expressing
M2 markers (CD206, and IL-10) [47,52]. These experiments indicated that tibia fracture enhanced
neuroinflammation during the acute stage of stroke.
Oxidative stress participated in the pathogenesis of ischemic or hemorrhagic stroke brain
injuries [53,54]. This process involves nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase [55], which is regulated by the inflammatory transcription factor, NF-κB [56]. Tibia fracture
reduced the expression of anti-oxidant genes [superoxide dismutase 1 (SOD1) and glutathione
peroxidase 1 (GPX1)] and increased phospho-NF-κB p65 positive microglia/macrophages and the
expression of the two subunits of pro-oxidative stress protein NADPH oxidase (gp91phox and p22phox)
in pMCAO and pMCAO plus tibia fracture mice [47,52].
Monoamine oxidase B (MAOB) is a type of MAO that is linked to oxidative stress in tissues [57].
Mice with tibia fracture one day after the pMCAO had more MAOB-positive astrocytes compared
with the pMCAO-only mice, which was associated with an increase of brain edema [58].
4. Inhibition of Inflammation Could Reduce the Negative Impact of Bone Fracture on Ischemic
Stroke Recovery
Patients suffering stroke and bone fracture often have unfavorable outcomes. In order to
improve the quality of life and cut down on the medical costs for patients suffering both injuries,
novel therapies are urgently needed. Animal studies show that neuroinflammation is one of the
underlying mechanisms of the negative impact of bone fracture on stroke recovery. In this section,
we will review some anti-inflammation strategies that have been tested in animals with bone fracture
and stroke.
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HMGB1 is a non-histone DNA-binding protein that is widely expressed in various tissues,
including brain [44,59]. HMGB1 is among the earliest-activated cytokines after surgical trauma,
causing neuroinflammation and cognitive impairment [44]. In adult mice, plasma levels of HMGB1
increased within 1 h after tibia fracture [44]. Many inflammatory conditions, such as aseptic trauma,
acute lung injury, arthritis and stroke engage the innate immune response through the passive release of
HMGB1 after cell lysis at sites of tissue damage [60]. By interaction with pattern-recognition receptors
(PRRs) on circulating bone marrow-derived monocytes, HMGB1 induces the synthesis and release of
pro-inflammatory cytokines including TNFα through the transcriptional upregulation of NF-κB [61],
disrupting BBB integrity and allowing the monocyte to infiltrate into the brain [44]. Concurrently,
studies show that HMGB1 increases expression of the monocyte chemoattractant protein-1 (MCP-1) in
the central nervous system [62]. Therefore, HMGB1 plays a key role in initiating the inflammatory
cascade after bone fracture.
Animal studies showed that neutralizing HMGB1 using an HMGB1-specific antibody
significantly ameliorated brain injury and neuronal deficits in rats subjected to MCAO [63].
Anti-HMGB1-neutralizing antibody decreased the BBB permeability of tibia fracture mice through
time-dependent inhibiting morphological changes of astrocyte and endothelial cells [60]. Neutralizing
HMGB1 also prevented the negative impact of tibia fracture on ischemic stroke injury, reducing infarct
size, behavioral dysfunction and macrophage/microglia infiltration [46].
IL-1β is also a key mediator of inflammatory response to trauma [64]. IL-1β contributes to both
innate and adaptive immunity [65]. Increasing plasma concentration of IL-1β after peripheral trauma,
such as tibia fracture, exerts concentration-dependent effects on hippocampal-dependent memory
dysfunction, and accentuates adverse neurological behavior outcomes and brain injury after ischemic
stroke [44]. The increase of BBB permeability during this process may due to the suppression effects
of IL-1β on sonic hedgehog (SHH) expression in astrocytes and downregulation of tight junction
(TJ) protein expression in endothelial cells [66,67]. Therefore, IL-1β could represent an attractive
therapeutic target to attenuate brain injury and cognitive decline caused by bone fracture.
It has been shown that pre-treatment with IL-1 receptor antagonist or genetically knockout
of IL-1 receptor mitigates the level of circulating IL-1β and hippocampal microgliosis in tibia
fracture mice [42]. Systemic infusion of anti-IL-1β monoclonal antibody after cerebral ischemia
insult attenuates the increase of IL-1β after ischemic incidence and BBB permeability [68]. Increased
central IL-1β activity impairs the consolidation of memories that depend on the hippocampal function
but have no effect on the consolidation of hippocampal-independent memories [69]. Conversely,
IL-1 has also been suggested to facilitate hippocampal-dependent learning and memory; the IL-1 type
one receptor (IL-1RI) null mice have deficits in tasks of visuospatial learning and memory [70].
These results may argue for a more careful and in-depth evaluation of the roles of endogenous IL-1 in
hippocampal-independent cognitive decline.
The cholinergic pathway has been found to inhibit cytokine release through a mechanism
that requires the α7 subunit-containing nicotinic acetylcholine receptors (nAChRs) [71].
Stimulating the cholinergic anti-inflammatory pathway by electrical or pharmacological methods
significantly suppresses the systemic levels of TNF and other pro-inflammatory cytokines during
endotoxemia [72–74]. The α7 nAChR subunit expressed on the surface of macrophages regulates
this pathway during inflammation [75]. Activation of α7 nAChR in macrophages dampens the
inflammatory response.
It has been shown that N-Methyl_D-aspartic acid (NMDA) receptor activation-induced
excitoxicity was avoided in rat neocortical neurons when dimethoxybenzylidene anabaseine
(DMXB), the α7 nicotinic acetylcholine receptor agonist, was added 24 h before NMDA addition.
Unlike muscarinic antagonists, nicotinic antagonists were able to nullify this neuroprotection.
Additionally, when rats were subjected to focal ischemic insults, infarct sizes were smaller in
rats that have received DMXB 24 h beforehand. Interestingly, these neuroprotective effects were
not present when DMXB was added simultaneously with either NMDA or focal ischemic insults.
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In a non-apoptotic model, α7 receptors seemed to provide neuroprotection when mecamylamine was
absent. Ultimately, the results imply that α7 receptors contribute to neuroprotection for ischemic
stroke, and that a mechanism exists in which intracellular calcium ion concentrations temporarily
increase via α7-activation and are accompanied by protein kinase C (PKC) activation.
Activation of the nAChR protects against ischemic stroke-related cerebral damage [76–78]
and reduces tibia fracture-induced systemic/hippocampal inflammation. It has been shown
that ischemic stroke is associated with the activation of the vagal cholinergic anti-inflammatory
pathway [79,80], which protects against ischemic stroke-related cerebral damage [76,77]. In addition,
α7 nAchRs protect against glutamate neurotoxicity and neuronal ischemic damage [78].
Activation of α7 nAChR reduces brain damage in a mouse intracerebral hemorrhage model [81]
and in a rat subarachnoid hemorrhage model [82]. Treating the mice withα7 nAChR agonists attenuates
the cognitive decline and hippocampal inflammation caused by bone fracture [83]. Treating mice with
a selective α7 nAChR agonists, PHA (PHA568487), reduced neuronal injury and functional deficits
of mice subjected pMCAO [52] or bone fracture one day after pMCAO [47]. PHA-treated mice had
fewer apoptotic neurons and CD68+ cells in the peri-infarct region. PHA treatment also decreased
oxidative stress and the number of pro-inflammatory macrophages (M1), and increased the number of
pro-recovery macrophage (M2). In addition to inhibiting inflammation, PHA treatment improved BBB
integrity and reduced MAOB-positive astrocytes and brain edema in mice subjected to bone fracture
one day after pMCAO [58]. Thus, modulating α7 nAchR activity could be developed into a novel
treatment to reduce the adverse influence of bone fracture on recovery in stroke patients.
However, it is well known that inflammation has bi-physiological roles in stroke recovery [84,85].
Simply inhibiting inflammation may not improve long-term outcomes of stroke patients [86]. Therefore,
the timing, dose and the types of anti-inflammatory agents have to be tested carefully before applying
to patients.
5. Milestone Studies in Understanding Bone Fracture and Stroke Interplay
Important investigations carried out by various laboratories over the past decade have contributed
to our understanding of how bone fracture may impact stroke pathology (Table 1).
Table 1. Milestone Discoveries.
Year Authors Major Discovery
2010 Cibelli et al. TNF-α an upstream mediator for hippocampal IL-1β followingtibia fracture
2010 Terrando et al. HMGB1 initiate inflammatory cascade post-bone fracture whichcauses cognitive dysfunction
2013 Degos et al. HMGB1 antibody reduces cell death in a fracture-enhanced stroke
2014 Han et al. α7 nAChR agonists diminishes microglia/macrophage infiltrationof the peri-infarct region
2014 Vacas et al. HMGB1 antibody decreased BBB permeability afterfracture-enhanced stroke
2016 Zou et al. PHA treatment attenuated brain edema and enhanced BBB integrityin fracture-enhanced stroke
Attempting to connect peripheral trauma to neurological decline, a group studied orthopedic
surgery mouse models to probe the mechanisms underlying postoperative cognitive dysfunction
(POCD) [42]. Specifically, they examined whether memory deficits and hippocampal inflammation
were initiated by surgical trauma-generated systemic inflammation. The researchers performed tibia
surgery on both interleukin-1 receptor knockout mice (IL-1R−/−) and wild-type mice, analyzed the
animals’ memory capabilities via fear-conditioning tests, and measured systemic and hippocampal
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cytokines and activated microglia. They found that the mice were afflicted with memory problems,
elevated plasma cytokines, and increased hippocampal reactive microgliosis and IL-1β transcription
and expression. Surgery-related memory deficits and neuroinflammation were alleviated with
minocycline treatment and inhibition of IL-1β in both IL-1R−/− mice and mice given an IL-1R
antagonist. Thus, they concluded that cognitive dysfunction following surgery is produced by
IL-1β-controlled hippocampal inflammation, which is elicited by an innate immune response to
peripheral surgical intervention.
The follow-up experiment demonstrated that HMGB1 increased immediately after bone fracture
and is an important mediator for post-bone fracture cognitive dysfunction [43]. Further probing the
potential overlap of systemic and central inflammatory pathways, which could contribute to bone
fracture-induced cognitive pathology, the authors employed a monoclonal antibody (mAb) against
HMGB1. They explored how anti-HMGB1 would exert neuroprotection when HMGB1 translocates
within the brain, when the blood-brain barrier (BBB) is disrupted, and when the brain experiences
edema. Moreover, the justification for this experiment was based on a past study by the same authors
in which rats with MCAO had abated brain infarcts when the same mAb was injected intravenously.
Rats were subjected to MCAO surgery to produce ischemic insult and via intravenous injection,
were either given anti-HMGB1 or a control IgG antibody. In MCAO rats, HMGB1 was released by
neurons and translocated within the brain in a time-sensitive manner. The anti-HMGB1 lessened brain
edema and inhibited the opening of inter-endothelial cell tight junctions, astrocyte end feet swelling
and detachment from the basal lamina. Additionally, BBB permeability was enhanced and endothelial
cells and pericytes underwent morphological changes when HMGB1 was incorporated in an in vitro
BBB model. The HMGB1 mAb successfully restricted these effects and led to dwindling HMGB1 serum
levels. Hence, ischemic stroke deficits could potentially be attenuated with the anti-HMGB1 mAb,
as demonstrated by the antibody’s ability to remove HMGB1, stymie brain edema, and safeguard
the BBB.
A study that induced tibia bone fracture one day after pMCAO in mice found an increase in infarct
volume, more severe neurobehavioral abnormalities, enhanced immune response, and increased
neuronal death when compared to stroke-only animals. This study probed the implications of
HMGB1 [46], reporting that intraperitoneal injection of HMGB1 in stroke-only animals mimicked the
bone fracture effects and increased the macrophage infiltration of stroke-only animals, whereas HMGB1
neutralization nullified the fracture-induced injury exacerbation in dual-injury animals. Authors
concluded that post-stroke bone fracture enhances macrophage infiltration via an HMGB1-dependent
mechanism, and that HMGB1 may be a promising target in minimizing the adverse consequences of
bone fracture following stroke.
In addition, activation of the α7 nAChR using it specific agonist PHA568487 (1) reduced CD68+
microglia/macrophages, (2) shifted microglial/macrophage polarization from M1 to M2, (3) reduced
apoptotic neurons, and (4) lessened oxidative damage in mice subjected to tibia fracture followed
by pMCAO one day later [47]. More specifically, authors found that that PHA568487 inhibits NF-κB
phosphorylation, down-regulates its activity, and lessens oxidative gene expression—all consistent
with their previous finding that PHA inhibits TNFα-induced NF-κB activation. Authors thus conclude
that α7 nAChR plays an important protective role in the stroke brain with and without tibia fracture.
In probing the effects of circulating pro-inflammatory cytokines on BBB permeability, a study
found that IL-1β contributes significantly to the loss of BBB integrity following stroke. By designing
an IL-1β-neutralizing antibody, this group demonstrated that intravenous administration of the
anti-IL-1β antibody was able to preserve BBB integrity following experimental stroke, although the
exact mechanisms of this change were not identified. Specifically, authors did not observe widespread
alterations in the expression of tight junction proteins such as Occludin, Claudin-1/5, or ZO-1/2
across various brain regions. Nonetheless, identifying systemic causative agents for increased BBB
permeability has important implications in our understanding of how systemic injuries may worsen
concurrent stroke pathology.
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Finally, a recent study connected multiple of the concepts discussed thus far by identifying the
ability of α7 nAChR activation with PHA568487 to reduce bone fracture-induced exacerbation of BBB
permeability following pMCAO stroke. Tibia fracture induced 1 day after stroke resulted in increased
brain water content and MAO-B-positive astrocytes, while PHA568487 treatment reversed these effects
and increased Claudin-5 expression. Furthermore, α7 nAChR inhibition with methyllycaconitine
resulted in the opposite effects. Taken together, this study indicates that in addition to the previously
mentioned mechanism of α7 nAChR, preservation of BBB integrity and decreased oxidative/astrocytic
damage may contribute to its protective properties [58].
6. Clinical Implications
Stroke is not only the fourth-leading cause of death in the United States [87], but is also
an important risk factor for bone fracture [6]. Stroke is also one of the most devastating complications
of bone fracture, occurring in 4% of patients in the first year after hip surgery [8]. Bone fracture patients
with post-fracture stroke have poor functional recovery and require more care in the first year after
bone fracture than those who do not have stroke [31]. The overall number of hip fractures is high
and is anticipated to exceed 6 million a year [32], which could increase with the increases of aged
population. The lifetime risk of hip fracture is 17.5% for women and 6% for men [33,88]. Hip fracture
patients are at a 1.54-fold higher risk of developing stroke than controls [89], at an incidence of 64.6 per
1000 persons per year [89]. The estimated occurrence of stroke after hip fracture is 64,600 per year.
Stroke and bone fracture share some common risk factors, such as hypertension and diabetes
mellitus [5,12]. However, management of these risk factors to prevent stroke or bone fracture is
contradictory. Stroke doubles the risk of developing dementia [10]. Cognitive impairment occurs in
nearly half of hip fracture patients [11]. Patients with both injuries will have worse outcomes than
patients that have single injury. How bone fracture increases ischemic injury in the brain is largely
unknown. Understanding the underlying mechanisms could lead to the discovery of new targets for
developing innovative therapies to improve the recovery of patients with stroke and bone fracture and
reduce the health care costs.
7. Future Directions
We have discussed the potential impact of bone fracture on stroke recovery and the underlying
mechanisms. However, there are still some questions that need to be clarified; for example,
the incidence of post-bone fracture cognitive dysfunction in humans needs more investigation.
Surgery remains the most effective treatment method for bone fracture, and due to the
cognitive dysfunction associated with glucocorticoid exposure, anesthesia type [90,91] and surgery
procedures [92], it is important to avoid potential secondary injury among stroke patients. Although
increasing evidence shows that inflammatory and immune activities play important roles in the
decline of cognitive function of bone fracture patients, and some human trials have reported that
anti-inflammation decreases the frequency of post-operative cognitive dysfunction, the selection
of correct anti-inflammation agents needs to be made cautiously, because some agents can cause
unwanted side effects [93].
In addition, bone fracture causes acute pain and chronic pain, which can last long after the fracture.
A multivariate regression analysis revealed that post-operative analgesia was associated with the
development of post-operative cognitive dysfunction [94]. Therefore, the impact of pain on stroke
recovery needs to be studied in the future.
In summary, numerous studies over the past decade have reported the impact of bone fracture
on cognitive function and stroke recovery. However, the mechanism remains largely unknown.
We anticipate that more vigorous and longitudinal studies would help to uncover the underlying
mechanisms and develop new intervention strategies to improve the recovery of patients with stroke
and bone fracture.
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